.Attributes Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA study, after an average follow-up of 11 months, clients with metastatic intestinal growths that acquired biomarker-matched therapies based on distributing growth DNA profiling showed a greater scientific perk than those receiving unequaled therapy.